Full-Time
Corporate FP&A Director
Cellares
201-500 employees
Integrated development and automated manufacturing platform
Compensation Overview
$170k - $240k/yr
San Bruno, CA, USA
Hybrid
Bachelor's
 Finance & Banking (1) |
|---|
Get referred to Cellares
See people who can refer or advise you
- Bachelor’s degree in finance, accounting, or a related field
- 10+ years of relevant demonstrated financial and leadership experience, preferably in biotech, pharma, life sciences, or manufacturing
- Extensive experience with SAP or other relevant ERP solutions
- Experience with analysis tools and databases such as Power Query, Python, SQL, Power BI, Snowflake, and Tableau
- Highly organized with a meticulous attention to detail and the willingness to be in a hands-on position
- Deep understanding of industry financials
- Proven track record of financial leadership in a fast-paced, dynamic environment
- Strong analytical and problem-solving skills, with the ability to synthesize complex information into clear recommendations
- Excellent communication and interpersonal skills, with the ability to work effectively with both internal teams and external partners
- Lead corporate financial planning processes, including annual operating plan, quarterly forecasts, and monthly budget-to-actual analysis
- Partner with department leaders to align headcount, operating expenses, and capital investments with company milestones
- Build and maintain financial models for cash flow forecasting, scenario planning, and long-range planning
- Provide analysis to evaluate manufacturing cost structures, R&D investment priorities, and commercial launch economics
- Prepare monthly and quarterly management reports with performance commentary for leadership
- Collaborate with Accounting to ensure accurate month-end close and reporting
- Support the preparation of Board and investor materials, including financial updates and KPI's
- Identify opportunities to improve forecasting accuracy, process efficiency, and data integrity
Cellares provides integrated development and manufacturing for cell therapies through its IDMO model, bringing therapy development and production under one roof. Its Smart Factory uses automated single-use cartridge technology and the Cell Shuttle Platform to run scalable cell therapy manufacturing with higher productivity and fewer errors. This setup differentiates Cellares from traditional CDMOs by offering end-to-end, in-house services for preclinical, clinical, and commercial programs, aiming to lower costs and speed up production. The goal is to accelerate the adoption of cell therapies by delivering cost-efficient, reliable manufacturing at scale.
Company Size
201-500
Company Stage
Series D
Total Funding
$682M
Headquarters
South San Francisco, California
Founded
2019
Get referred to Cellares
See people who can refer or advise you
Simplify's Take
What believers are saying
- Cabaletta Bio dosed first patients on Cellares-manufactured rese-cel in February 2026.
- June 15, 2026 Cellares expanded Series D to $327 million for buildout.
- July 21, 2026 Papillon and Sonoma partnerships broaden Cellares into rare disease and autoimmune markets.
What critics are saying
- 2027 commercial launch depends on Leiden and Kashiwa construction finishing on schedule.
- Bristol Myers Squibb's $380 million reservation concentrates revenue in one counterparty.
- If automation fails outside controlled demos, Cellares loses its IDMO thesis and IPO narrative.
What makes Cellares unique
- FDA AMT designation in March 2025 gave Cell Shuttle regulatory advantage.
- June 2026 investors BlackRock, T. Rowe Price, and Prime Radiant validate the platform.
- Cellares spans clinical and commercial manufacturing across Bridgewater, Leiden, and Japan.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Stock Options
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -1%2 year growth
↓ -2%Cellares and Papillon Therapeutics partner to automate manufacturing of PPL-001 for patients with Friedreich's Ataxia. July 21, 2026 | Collaboration will apply Cellares' Cell Shuttle(R) and Cell Q(TM) platforms to PPL-001, an investigational hematopoietic stem cell therapy for a rare multi-systemic pediatric disease SOUTH SAN FRANCISCO, Calif. & SAN DIEGO-(BUSINESS WIRE)-Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and Papillon Therapeutics Inc., a clinical-stage biotechnology company advancing a pipeline of multi-systemic genetic medicines directed at the underlying causes of inherited disease, today announced a collaboration to automate manufacturing of PPL-001, Papillon's investigational gene-corrected hematopoietic stem and progenitor cell (HSPC) therapy targeting Friedreich's ataxia. Friedreich's ataxia (FA) is a rare, inherited neurodegenerative disorder that affects multiple organ systems simultaneously, including the central nervous system, heart, skeletal muscle, and pancreas, and typically causes progressive loss of coordination and hypertrophic cardiomyopathy beginning most often in childhood and adolescence. PPL-001 uses targeted gene editing to correct the GAA repeat expansion in Intron 1 of the FXN gene, the mutation responsible for more than 95% of FA cases. The therapy has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA, and its development is supported in part by grants from the California Institute for Regenerative Medicine (CIRM), the Friedreich's Ataxia Research Alliance (FARA), and the National Institutes of Health (NIH). Under the collaboration, Cellares will translate the PPL-001 manufacturing process onto the Cell Shuttle(R), its end-to-end cell therapy manufacturing platform, and support release testing through the Cell Q(TM), its automated quality control and release testing system. The Cell Shuttle's closed-system, automated workflow is designed to improve reproducibility, reduce process variability, and lower manufacturing costs for HSPC-based therapies that require precise handling and analytical control at each stage of production. "Friedreich's ataxia is a devastating disease that begins most often in childhood and adolescence, and PPL-001 represents an innovative approach to addressing its underlying genetic cause," said Carter Cliff, Chief Executive Officer of Papillon Therapeutics. "Delivering consistent gene correction across a patient-derived CD34+ population requires a level of process control that manual manufacturing simply cannot guarantee. Cellares' manufacturing platform enables that capability at scale and this collaboration is a critical step toward clinical development and future commercial launch." The partnership reflects Cellares' ability to support cell therapy programs across a broad spectrum of manufacturing scales, from rare pediatric indications with small patient populations to large autoimmune programs requiring hundreds of thousands of doses per year. For developers like Papillon, Cellares provides flexible manufacturing infrastructure and predictable economies of scale required to support both near-term clinical trials and global commercial production. "The cell therapy field tends to focus on the largest patient populations, but the manufacturing challenges facing rare disease developers are just as real and often harder to solve," said Fabian Gerlinghaus, Co-founder and Chief Executive Officer of Cellares. "PPL-001 is a scientifically compelling program targeting a disease with no approved curative treatment, and the Cell Shuttle and Cell Q are built to deliver the precision and process consistency that a gene-corrected HSPC therapy requires to reach more patients faster." About Papillon Therapeutics Papillon is dedicated to delivering cures from within by harnessing the body's own cells. Overcoming the targeting barriers of traditional genetic medicines, the company's proprietary platform utilizes patient-derived hematopoietic stem cells to systemically distribute functional proteins across multiple affected organs. Papillon's lead program, PPL-001, is a one-time, potentially lifetime-durable treatment designed to arrest the progression of Friedreich's ataxia across affected tissues - including the brain, spine, heart, and pancreas. Validated by a landmark clinical partnership with Novartis, Papillon is advancing a pipeline of transformative cell therapies engineered to restore health across a lifetime. For more information, visit https://papillon-tx.com/ and follow Papillon on LinkedIn. About Cellares Cellares is the first Integrated Development and Manufacturing Organization (IDMO), providing global cell therapy development and manufacturing services through an Industry 4.0 approach to the mass manufacture of the living drugs of the 21st century. The company enables drug sponsors to develop, scale, and commercialize cell therapies with the capacity, reliability, and economics required to meet total patient demand. Cellares' fully automated platforms - Cell Shuttle(R) for end-to-end cell therapy manufacturing and Cell Q(TM) for automated in-process and release quality control - are deployed across its network of IDMO Smart Factories worldwide. These technologies deliver industry-leading manufacturing economics, higher process success rates, and the ability to produce up to 10x more cell therapy batches than conventional CDMOs with comparable footprint and headcount, resulting in the lowest cost of manufacturing in the industry. The Cell Shuttle is the first cell therapy manufacturing platform to receive the FDA's Advanced Manufacturing Technology (AMT) designation, and has demonstrated a 100% automation success rate across more than a dozen automated processes. Cellares has achieved key clinical validation milestones, including a successful IND Amendment enabling active clinical manufacturing on the Cell Shuttle platform, and the successful dosing of first patients in a partner clinical trial - marking the platform's transition from development-stage technology to clinically validated manufacturing infrastructure. These milestones span multiple therapeutic areas and cell therapy modalities, including both oncology and autoimmune indications. Headquartered in South San Francisco, California, Cellares operates its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey, with additional facilities under construction in Europe and Japan. Through its global manufacturing network, Cellares is purpose-built to support both clinical and commercial programs and to expand access to life-saving cell therapies worldwide. For more information, visit www.cellares.com and follow Cellares on LinkedIn. Cellares Contacts Business Development: [email protected] Investors: [email protected] Media: [email protected] Papillon Therapeutics Contacts Business Development: [email protected] Investors: [email protected] Media: [email protected]
Cellares and Sonoma Biotherapeutics collaborate to automate manufacturing of SBT-77-7101 engineered Treg cell therapy on the Cell Shuttle(R) platform. First regulatory T cell program to onboard to the Cell Shuttle, bringing automated cGMP manufacturing and QC infrastructure to Treg cell therapies SOUTH SAN FRANCISCO, Calif. & SEATTLE-(BUSINESS WIRE)-Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced a collaboration to automate manufacturing of lead SonomaBio(R) program, SBT-77-7101, on the Cellares Cell Shuttle. SBT-77-7101 is an autologous CAR-Treg cell therapy in Phase 1 clinical development for poly-refractory rheumatoid arthritis (RA), the most challenging RA patients, who have exhausted all available treatment options. The program is the first Treg cell therapy to onboard to the Cell Shuttle, extending Cellares' automated manufacturing platform into a modality that demands precise handling and analytical control to preserve Treg identity and function. Under the collaboration, Cellares will translate SonomaBio's proprietary SBT-77-7101 manufacturing process onto the Cell Shuttle and automate in-process and release testing through Cell Q(TM), Cellares' automated quality control system. Treg manufacturing is among the most labor-intensive and sensitive processes in cell therapy, a challenge that becomes acute at scale. With a global manufacturing network and automated platforms, Cellares can build on Sonoma's deep Treg understanding to deliver the economics and throughput to advance SBT-77-7101 toward late-stage clinical trials and commercial readiness. Cellares operates its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey, with additional facilities under construction in Europe and Japan, providing partners with a global manufacturing footprint built to support cell therapies from Phase 1 to commercial scale. "Tregs are uniquely sensitive to the manufacturing process, and the precision of our proprietary process drives their superior function. Cellares brings the Cell Shuttle platform, and global infrastructure to help us deliver on our clinical ambitions at scale for the hardest-to-treat RA patients," said Stephen Dilly, MBBS, PhD, President, Chief Executive Officer and Board Chair of Sonoma Biotherapeutics. "Every new cell therapy modality we bring to the Cell Shuttle and Cell Q expands what is possible for the field and for patients in need," said Fabian Gerlinghaus, Co-founder and Chief Executive Officer of Cellares. "Tregs are among the most technically demanding cell types to manufacture reliably. We are honored to partner with SonomaBio, the industry leader in this field, and demonstrate that our platform, which has already been robustly validated for CAR-T therapies in the clinic, can directly translate to Tregs. Built on Nobel-Prize-winning science, SonomaBio has developed one of the most advanced Treg programs in the clinic and we look forward to contributing to their clinical success as they bring this groundbreaking therapy to patients." About Sonoma Biotherapeutics Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring immune system balance. Founded by pioneers in Treg biology and cell therapy, including Dr. Fred Ramsdell, whose foundational research in Treg biology was recognized with a 2025 Nobel Prize, Sonoma Biotherapeutics combines deep scientific expertise with proprietary platform technologies to advance a new generation of targeted and durable Treg cell therapies. In addition to its lead, proprietary Treg program, SBT-77-7101, Sonoma Biotherapeutics is collaborating with Regeneron to advance a pipeline of Treg cell therapies for autoimmune diseases. About Cellares Cellares is the first Integrated Development and Manufacturing Organization (IDMO), providing global cell therapy development and manufacturing services through an Industry 4.0 approach to the mass manufacture of the living drugs of the 21st century. The company enables drug sponsors to develop, scale, and commercialize cell therapies with the capacity, reliability, and economics required to meet total patient demand. Cellares' fully automated platforms - Cell Shuttle(R) for end-to-end cell therapy manufacturing and Cell Q(TM) for automated in-process and release quality control - are deployed across its network of IDMO Smart Factories worldwide. These technologies deliver industry-leading manufacturing economics, higher process success rates, and the ability to produce up to 10x more cell therapy batches than conventional CDMOs with comparable footprint and headcount, resulting in the lowest cost of manufacturing in the industry. The Cell Shuttle is the first cell therapy manufacturing platform to receive the FDA's Advanced Manufacturing Technology (AMT) designation, and has demonstrated a 100% automation success rate across more than a dozen automated processes. Cellares has achieved key clinical validation milestones, including a successful IND Amendment enabling active clinical manufacturing on the Cell Shuttle platform, and the successful dosing of first patients in a partner clinical trial - marking the platform's transition from development-stage technology to clinically validated manufacturing infrastructure. These milestones span multiple therapeutic areas and cell therapy modalities, including both oncology and autoimmune indications. Headquartered in South San Francisco, California, Cellares operates its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey, with additional facilities under construction in Europe and Japan. Through its global manufacturing network, Cellares is purpose-built to support both clinical and commercial programs and to expand access to life-saving cell therapies worldwide. For more information, visit www.cellares.com and follow Cellares on LinkedIn. Cellares Contacts Business Development: [email protected] Investors: [email protected] Media: [email protected] July 13th, 2026 July 12th, 2026 July 11th, 2026 July 10th, 2026
Cellares, a cell therapy development and manufacturing company, has raised $327 million in Series D funding, according to SEC filings. Investors include Prime Radiant, ARK Invest, BlackRock, Eclipse, T. Rowe Price, Duquesne Family Office, Baillie Gifford, Intuitive Ventures and others. The South San Francisco-based company operates as an Integrated Development and Manufacturing Organisation, providing automated cell therapy manufacturing through its Cell Shuttle platform. The platform has received FDA's Advanced Manufacturing Technology designation and demonstrated 100% automation success across more than a dozen processes. Cellares currently operates a commercial-scale facility in Bridgewater, New Jersey, with additional facilities under construction in Europe and Japan. The company aims to make cell therapies more accessible through automated, scalable manufacturing solutions.
Which biotechs have raised new VC financing this week? Its latest roundup of venture capital financings in the biotech sector includes solid eight-figure rounds for Triveni, Cellares, HMNC, Vedana, and Neion Bio. Triveni aims to take second eczema drug into phase 2. Watertown, Massachusetts biotech Triveni Bio has added $65 million to its cash reserves after completing a Series C funding round that will support a phase 2 trial of its TRIV-573 candidate in atopic dermatitis, which is due to start later this year. The round was co-led by new investors Ascenta Capital and Janus Henderson Investors, with participation from Deep Track Capital, alongside additional existing investors. TRIV-573 is a long-acting bispecific drug that simultaneously inhibits IL-13 - a well-established target in AD treatment - as well as the emerging target KLK5/7 (kallikrein-related peptidases 5 and 7). Triveni's lead drug, TRIV-509, is a KLKR5/7 targeted antibody already in a phase 2 proof-of-concept study in AD. The financing, which follows a $92 million Series A in 2023 and $115 million in a 2024 second round, has been announced a few days after Triveni started a first-in-human trial of the bispecific candidate. Cellares adds $50m to Series D, taking it to a massive $327m. Contract cell therapy manufacturer, Cellares, has made its already supersized fourth-round financing even bigger, raising another $50 million from Prime Radiant Partners that brings the total to $327 million. Cellares applies robotics and other automation technologies in a 'smart factory' approach designed to speed up the whole cell therapy production process, from cell culture to quality control, at clinical and commercial scale, and is already being used to produce CAR-T therapies for Bristol Myers Squibb under a $380 million deal signed in 2024. The funding will help the company complete a manufacturing facility under construction in Leiden, the Netherlands, that is due to go live in 2027 and complement an existing facility in New Jersey, US. Brain health biotech HMNC raises $50m, and appoints CMO. HMNC Brain Health has closed the first $50 million tranche of a Series B financing, led by German healthcare company MEDICE, with the proceeds earmarked to prepare for phase 3 trials of Ketabon (KET01), an oral prolonged-release ketamine formulation, and Nelivabon (BH-200), a potential first-in-class oral vasopressin V1b receptor antagonist. Both are experimental therapies for depression. In connection with the round, which was joined by existing investor The Maschmeyer Group, MEDICE has also licensed exclusive European commercial rights for Ketabon, in return for a commitment to pay Munich, Germany-based HMNC double-digit royalties on net sales and milestone payments for meeting sales targets. Meanwhile, in preparation for the forthcoming clinical trials programme, HMNC has named former Lundbeck head of clinical development, Dr Bjørn Grønning, as its chief medical officer. Vedana Therapeutics takes on migraine prevention mission. Vedana Therapeutics has emerged from the biotech shadows with $46 million in first-round financing, co-led by Westlake BioPartners and Canaan Partners, and a plan to improve on current migraine prevention therapies based on CGRP inhibitors. The Seattle, Washington biotech, which wants to help the approximately two-thirds of migraine patients who cannot control their headaches with current drugs, has two candidates in its pipeline, including an antibody directed at PACAP - another peptide thought to play a role in migraine - and a dual PACAP/CGRP inhibitor. Both are still in preclinical development, with first-in-human trials scheduled to start in 2027. The round was also supported by Dawn Biopharma and Alexandria Venture Investments. Neion hatches $23m Series A for egg manufacturing. New York's Neion Bio, which is working on an egg-based manufacturing platform for biologic medicines, has raised $23 million in Series A financing. It is using chicken eggs as "biological vessels" to produce and stabilise proteins in a sterile environment and "at meaningful scale within days." The financing was led by Caffeinated Capital, with participation from new investors Digitalis Ventures, Ensemble VC, and Trust Ventures, alongside returning backers that include Haystack and Basis Set Ventures. Meanwhile, Neion has also just announced its first commercial co-development and supply agreement, to make biosimilar medicines for an undisclosed pharma company. 19 June, 2026
Prime Radiant Partners makes $50 million inaugural growth investment in Cellares' $327 million Series D round to accelerate global automated cell therapy manufacturing. Published on June 16, 2026 StartupNews.fyi Editorial Team The global life sciences and healthcare sectors are undergoing a massive technological evolution, spurred by automation, artificial intelligence (AI), and next-generation therapeutic modalities. In a significant move impacting the transatlantic biotechnology landscape, newly formed private equity advisory firm Prime Radiant Partners ("Prime Radiant") has announced a $50 million growth equity investment in Cellares. The investment was executed via the Prime Radiant Fund SLP SICAV-RAIF, a Luxembourg-based alternative investment fund advised by the firm. This transaction marks the firm's inaugural investment since its official launch in 2025. This $50 million commitment forms a vital part of Cellares' larger $327 million Series D funding round. The capital injection will directly support Cellares' mission to alleviate manufacturing bottlenecks in the cell and gene therapy (CGT) sectors, accelerate patient access to life-saving living drugs, and expand its global footprint of automated, scalable manufacturing facilities across North America, Europe, and Asia. The transatlantic private equity play: driving healthcare innovation. Headquartered across key international financial and biotech hubs with offices in New York, Milan, and Munich, Prime Radiant focuses specifically on middle-market private equity opportunities. The firm targets high-growth, innovation-driven companies delivering critical outsourced services, drug production technologies, and healthcare software solutions across North America and Europe. Founded by veteran industry executives Giovanni Fazio, Walid Gardezi, and Peter Soelkner, the Prime Radiant leadership team brings more than 70 years of collective operational and investment experience across private equity, life sciences, and pharmaceutical services. By deploying its first major allocation into Cellares, the firm signals its deep conviction in automated, Industry 4.0 infrastructure as the future of the global bioeconomy. Dissecting Cellares' IDMO model: overcoming the CDMO bottleneck. Traditional cell therapy manufacturing relies heavily on conventional Contract Development and Manufacturing Organizations (CDMOs). These legacy frameworks suffer from high labor requirements, large cleanroom footprints, high production costs, and an elevated risk of human error or process failure. Cellares directly disrupts this outdated system by establishing itself as the world's first Integrated Development and Manufacturing Organization (IDMO). Core advantages of the Cellares IDMO architecture: * Massive Throughput Scaling: The proprietary platform allows biopharmaceutical clients to produce up to 10 times more cell therapy batches than conventional CDMOs within an equivalent physical facility footprint and headcount. * Substantial Cost Reduction: By replacing manual interventions with end-to-end hardware and software integration, Cellares delivers significantly lower per-patient manufacturing costs. * Minimized Process Failure Rates: Closed, automated systems systematically remove manual touchpoints, driving down contamination risks and ensuring high reproducibility. * Dual-Platform Synchronization: The ecosystem relies on the Cell Shuttle(R) for end-to-end automated physical manufacturing alongside Cell Q(TM) for automated, real-time, in-process quality control and release testing. Regulatory Validation and global operational footprint. Cellares has transitioned from an advanced development-stage technology provider into a fully validated, clinically operational manufacturing powerhouse. The platform has achieved critical milestones that confirm its readiness for global commercialization across multiple therapeutic indications, including oncology and autoimmune diseases. Key milestones and expansion indicators: * FDA Designation: The Cell Shuttle is the first cell therapy manufacturing platform to receive the U.S. Food and Drug Administration's (FDA) Advanced Manufacturing Technology (AMT) designation, registering a 100% automation success rate across more than a dozen distinct processes. * Clinical Trial Validation: The platform successfully achieved an Investigational New Drug (IND) Amendment, enabling active clinical manufacturing on the Cell Shuttle and leading to the successful dosing of the first patients in an active partner clinical trial. * Strategic Manufacturing Footprint: Headquartered in South San Francisco, California, Cellares operates its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. To build a resilient global supply chain, additional commercial-scale smart facilities are currently under construction in Europe and Japan. A high-caliber global investor coalition. By anchoring its inaugural deal within Cellares' Series D round, Prime Radiant joins a sophisticated group of global institutional life sciences and growth technology investors. This collaborative capitalization highlights the market's collective demand for standardized, automated biotechnology infrastructure. Prominent Series D co-investors include: * Institutional Asset Managers: Funds managed by BlackRock, T. Rowe Price Investment Management, Inc., and Baillie Gifford. * Venture Capital & Growth Specialists: Eclipse, DFJ Growth, and ARK Invest. * Sovereign Wealth & Strategic Corporate Venture Arms: EDBI (Singapore), Gates Frontier, Duquesne Family Office, Intuitive Ventures, DC Global Ventures, and Willett Advisors. Executive perspectives: Scaling sustainable bio-infrastructure. The transaction brings together deep operational expertise and specialized sector capital to fundamentally reshape how advanced biologics move from the laboratory environment directly to the patient's bedside. Walid Gardezi, Co-Founder and Partner at Prime Radiant, noted: "The global healthcare market is undergoing a significant period of transformation driven by the launches of next-generation therapies and adoption of advanced technologies to improve patient care, while facing crosscurrents from increased regulatory complexity and aging populations across the world. Cellares represents our strategy at work as we seek to partner with exceptional management teams and companies to accelerate growth and drive innovation to improve human health." Fabian Gerlinghaus, Co-Founder and CEO of Cellares, highlighted the value of operationally grounded capital: "Prime Radiant's founders built their careers inside drug production and outsourced pharma services, so they understand the economics of the model Cellares is reshaping from firsthand experience. When investors with that background make you their first investment, it reflects real conviction in Cellares' IDMO model which integrates world-class tools and integrated automation to offer global biopharmaceutical manufacturing services. As we expand our network of IDMO Smart Factories into the United States, Europe, and Japan, their operational expertise will be invaluable." Peter Soelkner, Co-Founder and Partner at Prime Radiant, added: "Cellares is a company with world-class technology and a unique value proposition, which has the potential to fundamentally change market dynamics and how cell therapies reach patients at scale globally. We look forward to supporting Fabian and his team alongside a distinguished group of co-investors as they continue to scale and expand their footprint globally." Giovanni Fazio, Co-Founder and Partner at Prime Radiant, stated: "Our inaugural investment reflects both the strength of the Cellares platform and our conviction in the future of cell and gene therapy manufacturing. It is the first chapter in advising what we believe will be a distinctive portfolio of companies driving the next phase of healthcare and life sciences innovation, and we are just getting started." Through this transatlantic growth capital injection, Prime Radiant positions its advised fund at the absolute forefront of the automated bioeconomy, addressing the primary capacity and economic constraints currently limiting the scalability of 21st-century medicine. Disclaimer. Startupnews strive to uphold the highest ethical standards in all of its reporting and coverage. Startupnews StartupNews.fyi want to be transparent with its readers about any potential conflicts of interest that may arise in its work. It's possible that some of the investors Startupnews feature may have connections to other businesses, including competitors or companies Startupnews write about. However, Startupnews want to assure its readers that this will not have any impact on the integrity or impartiality of its reporting. Startupnews is committed to delivering accurate, unbiased news and information to its audience, and Startupnews will continue to uphold its ethics and principles in all of its work. Thank you for your trust and support.